FIELD: biotechnology.
SUBSTANCE: invention discloses an anti-CTGF antibody, a nucleic acid molecule coding the antibody, a host cell for producing the antibody, a pharmaceutical composition. Invention also relates to a method for determining CTGF and a method of treating or preventing a disease associated with CTGF.
EFFECT: invention can find application in therapy of diseases and conditions associated with CTGF, such as fibrotic diseases, hypertension, diabetes, myocardial infarction, arthritis, cell proliferative disease associated with CTGF, atherosclerosis, glaucoma or cancer.
18 cl, 2 dwg, 27 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
